221 related articles for article (PubMed ID: 18996426)
1. A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice.
Pérez JL; Acevedo R; Callicó A; Fernández Y; Cedré B; Año G; González L; Falero G; Talavera A; Pérez O; García L
Vaccine; 2009 Jan; 27(2):205-12. PubMed ID: 18996426
[TBL] [Abstract][Full Text] [Related]
2. Intranasal administration of proteoliposome-derived cochleates from Vibrio cholerae O1 induce mucosal and systemic immune responses in mice.
Acevedo R; Callicó A; del Campo J; González E; Cedré B; González L; Romeu B; Zayas C; Lastre M; Fernández S; Oliva R; García L; Pérez JL; Pérez O
Methods; 2009 Dec; 49(4):309-15. PubMed ID: 19545630
[TBL] [Abstract][Full Text] [Related]
3. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
Kundu J; Mazumder R; Srivastava R; Srivastava BS
FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752
[TBL] [Abstract][Full Text] [Related]
4. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
[TBL] [Abstract][Full Text] [Related]
5. Variable gene family usage of protective and non-protective anti-Vibrio cholerae O1 LPS antibody heavy chains.
Wade TK; Wade WF
Microbiol Immunol; 2008 Dec; 52(12):611-20. PubMed ID: 19120975
[TBL] [Abstract][Full Text] [Related]
6. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
[TBL] [Abstract][Full Text] [Related]
7. A Vibrio cholerae serogroup O1 vaccine candidate against CTX ET Phi infection.
Yan M; Liu G; Diao B; Qiu H; Zhang L; Liang W; Gao S; Kan B
Vaccine; 2007 May; 25(20):4046-55. PubMed ID: 17428586
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F
Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255
[TBL] [Abstract][Full Text] [Related]
9. A duplex vibriocidal assay to simultaneously measure bactericidal antibody titers against Vibrio cholerae O1 Inaba and Ogawa serotypes.
Yang JS; Choi S; Kim DD; Kang SS; Yun CH; Lee K; Han SH
J Microbiol Methods; 2009 Dec; 79(3):289-94. PubMed ID: 19796659
[TBL] [Abstract][Full Text] [Related]
10. Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice.
Tarique AA; Kalsy A; Arifuzzaman M; Rollins SM; Charles RC; Leung DT; Harris JB; Larocque RC; Sheikh A; Bhuiyan MS; Saksena R; Clements JD; Calderwood SB; Qadri F; Kovác P; Ryan ET
Clin Vaccine Immunol; 2012 Apr; 19(4):594-602. PubMed ID: 22357651
[TBL] [Abstract][Full Text] [Related]
11. Oral vaccination with Lactococcus lactis expressing the Vibrio cholerae Wzm protein to enhance mucosal and systemic immunity.
Zamri HF; Shamsudin MN; Rahim RA; Neela V
Vaccine; 2012 May; 30(21):3231-8. PubMed ID: 22426330
[TBL] [Abstract][Full Text] [Related]
12. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.
Islam K; Hossain M; Kelly M; Mayo Smith LM; Charles RC; Bhuiyan TR; Kováč P; Xu P; LaRocque RC; Calderwood SB; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB; Qadri F; Ryan ET
PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006376. PubMed ID: 29624592
[TBL] [Abstract][Full Text] [Related]
13. Transcutaneous immunization with toxin-coregulated pilin A induces protective immunity against Vibrio cholerae O1 El Tor challenge in mice.
Rollenhagen JE; Kalsy A; Cerda F; John M; Harris JB; Larocque RC; Qadri F; Calderwood SB; Taylor RK; Ryan ET
Infect Immun; 2006 Oct; 74(10):5834-9. PubMed ID: 16988262
[TBL] [Abstract][Full Text] [Related]
14. Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009.
Chowdhury MI; Sheikh A; Qadri F
Expert Rev Vaccines; 2009 Dec; 8(12):1643-52. PubMed ID: 19943759
[TBL] [Abstract][Full Text] [Related]
15. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
Chen WH; Cohen MB; Kirkpatrick BD; Brady RC; Galloway D; Gurwith M; Hall RH; Kessler RA; Lock M; Haney D; Lyon CE; Pasetti MF; Simon JK; Szabo F; Tennant S; Levine MM
Clin Infect Dis; 2016 Jun; 62(11):1329-1335. PubMed ID: 27001804
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of enteric-coated tablets as a whole cell inactivated vaccine candidate against Vibrio cholerae.
Fernández S; Año G; Castaño J; Pino Y; Uribarri E; Riverón LA; Cedré B; Valmaseda T; Falero G; Pérez JL; Infante JF; García LG; Solís RL; Sierra G; Talavera A
Travel Med Infect Dis; 2013; 11(2):103-9. PubMed ID: 23492079
[TBL] [Abstract][Full Text] [Related]
17. The study of intestinal immunity against V. cholerae: purification of V. cholerae El Tor haemagglutinin and the protective role of its antibody in experimental cholera.
Chaicumpa W; Atthasishtha N
Southeast Asian J Trop Med Public Health; 1979 Mar; 10(1):73-80. PubMed ID: 483020
[TBL] [Abstract][Full Text] [Related]
18. Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera.
Johnson RA; Uddin T; Aktar A; Mohasin M; Alam MM; Chowdhury F; Harris JB; LaRocque RC; Bufano MK; Yu Y; Wu-Freeman Y; Leung DT; Sarracino D; Krastins B; Charles RC; Xu P; Kovác P; Calderwood SB; Qadri F; Ryan ET
Clin Vaccine Immunol; 2012 Nov; 19(11):1712-21. PubMed ID: 22993410
[TBL] [Abstract][Full Text] [Related]
19. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response.
Mahalanabis D; Ramamurthy T; Nair GB; Ghosh A; Shaikh S; Sen B; Thungapathra M; Ghosh RK; Pazhani GP; Nandy RK; Jana S; Bhattacharya SK
Vaccine; 2009 Jul; 27(35):4850-6. PubMed ID: 19523608
[TBL] [Abstract][Full Text] [Related]
20. Immunological properties of complex conjugates based on Vibrio cholerae O1 Ogawa lipopolysaccharide antigen.
Paulovicová E; Machová E; Hostacká A; Bystrický S
Clin Exp Immunol; 2006 Jun; 144(3):521-7. PubMed ID: 16734622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
